Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Human Brain Collection Core, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland.
Cancer Immunol Res. 2019 Sep;7(9):1547-1561. doi: 10.1158/2326-6066.CIR-18-0367. Epub 2019 Jul 30.
Elevated CD47 expression in some cancers is associated with decreased survival and limited clearance by phagocytes expressing the CD47 counterreceptor SIRPα. In contrast, elevated CD47 mRNA expression in human melanomas was associated with improved survival. Gene-expression data were analyzed to determine a potential mechanism for this apparent protective function and suggested that high CD47 expression increases recruitment of natural killer (NK) cells into the tumor microenvironment. The CD47 ligand thrombospondin-1 inhibited NK cell proliferation and CD69 expression NK cells correspondingly displayed augmented effector phenotypes, indicating an inhibitory function of CD47 on NK cells. Treating human NK cells with a CD47 antibody that blocks thrombospondin-1 binding abrogated its inhibitory effect on NK cell proliferation. Similarly, treating wild-type mice with a CD47 antibody that blocks thrombospondin-1 binding delayed B16 melanoma growth, associating with increased NK cell recruitment and increased granzyme B and interferon-γ levels in intratumoral NK but not CD8 T cells. However, B16 melanomas grew faster in than in wild-type mice. Melanoma-bearing mice exhibited decreased splenic NK cell numbers, with impaired effector protein expression and elevated exhaustion markers. Proapoptotic gene expression in NK cells was associated with stress-mediated increases in mitochondrial proton leak, reactive oxygen species, and apoptosis. Global gene-expression profiling in NK cells from tumor-bearing mice identified CD47-dependent transcriptional responses that regulate systemic NK activation and exhaustion. Therefore, CD47 positively and negatively regulates NK cell function, and therapeutic antibodies that block inhibitory CD47 signaling can enhance NK immune surveillance of melanomas.
在某些癌症中,CD47 表达水平升高与存活时间缩短以及表达 CD47 反向受体 SIRPα 的吞噬细胞清除能力受限有关。相反,人类黑色素瘤中 CD47 mRNA 表达水平升高与生存时间改善相关。对基因表达数据进行分析以确定这种明显保护功能的潜在机制,并表明高 CD47 表达增加了自然杀伤 (NK) 细胞向肿瘤微环境的募集。CD47 配体血小板反应蛋白-1 抑制 NK 细胞增殖和 CD69 表达,而 NK 细胞相应地表现出增强的效应表型,表明 CD47 对 NK 细胞具有抑制作用。用阻断血小板反应蛋白-1 结合的 CD47 抗体处理人 NK 细胞可消除其对 NK 细胞增殖的抑制作用。同样,用阻断血小板反应蛋白-1 结合的 CD47 抗体处理野生型小鼠可延迟 B16 黑色素瘤的生长,与 NK 细胞募集增加以及肿瘤内 NK 细胞而非 CD8 T 细胞中颗粒酶 B 和干扰素-γ水平升高相关。然而,B16 黑色素瘤在 小鼠中生长更快。荷瘤 小鼠表现出脾 NK 细胞数量减少,效应蛋白表达受损,耗竭标志物升高。 NK 细胞中促凋亡基因的表达与应激介导的线粒体质子泄漏、活性氧和细胞凋亡增加有关。来自荷瘤小鼠的 NK 细胞的全基因组表达谱鉴定出依赖 CD47 的转录反应,这些反应调节 NK 细胞的全身性激活和耗竭。因此,CD47 正向和负向调节 NK 细胞功能,阻断抑制性 CD47 信号的治疗性抗体可以增强 NK 对黑色素瘤的免疫监视。